SG11201805594PA - Formulations for treating bladder cancer - Google Patents
Formulations for treating bladder cancerInfo
- Publication number
- SG11201805594PA SG11201805594PA SG11201805594PA SG11201805594PA SG11201805594PA SG 11201805594P A SG11201805594P A SG 11201805594PA SG 11201805594P A SG11201805594P A SG 11201805594PA SG 11201805594P A SG11201805594P A SG 11201805594PA SG 11201805594P A SG11201805594P A SG 11201805594PA
- Authority
- SG
- Singapore
- Prior art keywords
- formulations
- international
- pomona
- january
- bladder cancer
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 9
- 238000009472 formulation Methods 0.000 title abstract 7
- 206010005003 Bladder cancer Diseases 0.000 title abstract 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 title abstract 3
- 201000005112 urinary bladder cancer Diseases 0.000 title abstract 3
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229910003460 diamond Inorganic materials 0.000 abstract 2
- 239000010432 diamond Substances 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000003904 phospholipids Chemical class 0.000 abstract 2
- 241000581479 Apodichthys Species 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 229940123237 Taxane Drugs 0.000 abstract 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 abstract 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000008135 aqueous vehicle Substances 0.000 abstract 1
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- -1 paclitaxel Chemical class 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662275941P | 2016-01-07 | 2016-01-07 | |
| US201662275936P | 2016-01-07 | 2016-01-07 | |
| US201662421137P | 2016-11-11 | 2016-11-11 | |
| PCT/US2017/012720 WO2017120586A1 (en) | 2016-01-07 | 2017-01-09 | Formulations for treating bladder cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805594PA true SG11201805594PA (en) | 2018-07-30 |
Family
ID=59274569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805594PA SG11201805594PA (en) | 2016-01-07 | 2017-01-09 | Formulations for treating bladder cancer |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11229602B2 (zh) |
| EP (1) | EP3400072B1 (zh) |
| JP (3) | JP6697541B2 (zh) |
| KR (1) | KR20180103039A (zh) |
| CN (2) | CN113181118A (zh) |
| AU (1) | AU2017205337B2 (zh) |
| BR (1) | BR112018013896A2 (zh) |
| CA (1) | CA3009809A1 (zh) |
| CL (1) | CL2018001838A1 (zh) |
| CO (1) | CO2018007674A2 (zh) |
| CR (1) | CR20180388A (zh) |
| DK (1) | DK3400072T3 (zh) |
| EA (1) | EA038653B1 (zh) |
| ES (1) | ES2863659T3 (zh) |
| HK (1) | HK1255212A1 (zh) |
| IL (1) | IL260346B2 (zh) |
| MX (2) | MX2018008267A (zh) |
| MY (1) | MY198105A (zh) |
| PE (1) | PE20181445A1 (zh) |
| PH (1) | PH12018501451A1 (zh) |
| SG (1) | SG11201805594PA (zh) |
| WO (1) | WO2017120586A1 (zh) |
| ZA (1) | ZA201804968B (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018047074A1 (en) * | 2016-09-07 | 2018-03-15 | Cadila Healthcare Limited | Sterile injectable compositions comprising drug micelles |
| NZ753214A (en) | 2016-11-11 | 2022-02-25 | Univ Western Health Sciences | Methods of treating upper tract urothelial carcinomas |
| WO2018169960A1 (en) * | 2017-03-17 | 2018-09-20 | The Johns Hopkins University | Nanoparticle formulations for enhanced drug delivery to the bladder |
| LU101155B1 (en) * | 2017-07-19 | 2019-04-25 | Tesorx Pharma Llc | Liposomal Paclitaxel Formulation for Treating Bladder Cancer |
| EP3796965A4 (en) * | 2018-05-04 | 2022-01-26 | Lipac Oncology LLC | BALLOON CATHETER |
| MX2021005110A (es) * | 2018-11-02 | 2021-08-24 | Tesorx Pharma Llc | Quimioterapia intraperitoneal mejorada con liposomas. |
| GB201900389D0 (en) | 2019-01-11 | 2019-02-27 | Queens Univ Of Belfast | Solvent and water-free lipid-based nanoparticles and their methods of manufacture |
| CN113189315B (zh) * | 2021-04-13 | 2024-01-23 | 山东省医疗器械产品质量检验中心 | 评价抗菌导尿管抗菌活性的体外动态模型及其使用方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1330938C (en) | 1985-10-18 | 1994-07-26 | Abdul R. Khokhar | Hydrophobic cis-platinum complexes efficiently incorporated into liposomes |
| US5415869A (en) * | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
| US5902604A (en) | 1995-06-06 | 1999-05-11 | Board Of Regents, The University Of Texas System | Submicron liposome suspensions obtained from preliposome lyophilizates |
| ATE341310T1 (de) * | 2000-02-04 | 2006-10-15 | Lipoxen Technologies Ltd | Dehydratisierungs-/rehydratisierungsverfahren zur herstellung von liposome |
| US8658202B2 (en) * | 2001-04-25 | 2014-02-25 | Western University Of Health Sciences | Coated drug delivery formulations |
| DE60237162D1 (de) | 2001-10-03 | 2010-09-09 | Celator Pharmaceuticals Inc | Liposomenladung mit metallionen |
| BRPI0407096A (pt) | 2003-02-03 | 2006-01-24 | Neopharm Inc | Taxano encapsulado em lipossomo estável, estéril e filtrável e outros fármacos antineoplásicos |
| WO2005039534A1 (en) * | 2003-10-01 | 2005-05-06 | Children's Hospital & Research Center At Oakland | Lipophilic drug delivery vehicle and methods of use thereof |
| WO2005072776A2 (en) | 2004-01-30 | 2005-08-11 | Instytut Farmaceutyczny | Liposomal formulations of the antineoplastic agents |
| US20060024360A1 (en) * | 2004-07-28 | 2006-02-02 | Sd Pharmaceuticals, Inc. | Stable injectable composition of alpha tocopheryl succinate, analogues and salts thereof |
| NZ572601A (en) | 2006-03-29 | 2012-03-30 | Univ Wayne State | Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery |
| PT2076244T (pt) * | 2006-10-10 | 2017-03-09 | Jina Pharmaceuticals Inc | Sistemas aquosos para a preparação de compostos farmacêuticos à base de lípidos; composições, métodos e utilizações dos mesmos |
| CN101322689B (zh) * | 2007-06-11 | 2012-10-24 | 江苏先声药物研究有限公司 | 一种多西他赛长循环脂质体及其冻干粉针的制备方法 |
| WO2010009186A1 (en) * | 2008-07-15 | 2010-01-21 | The Board Of Trustees Of The University Of Illinois | Liposome formulation having hydrophilic and hydrophobic pharmaceutical compounds co-encapsulated therein |
| US8956600B2 (en) * | 2009-08-10 | 2015-02-17 | Taiwan Liposome Co. Ltd. | Ophthalmic drug delivery system containing phospholipid and cholesterol |
| WO2012094020A1 (en) * | 2010-01-07 | 2012-07-12 | Innopharma, Inc. | Methods and compositions for delivery of taxanes in stable oil-in-water emulsions |
| SG11201407349UA (en) * | 2012-05-09 | 2014-12-30 | Univ Western Health Sciences | Proliposomal testosterone formulations |
| CN103570766B (zh) | 2012-08-09 | 2016-04-13 | 浙江海昶生物医药技术有限公司 | 一种新型铂类脂质体制剂及其制备方法 |
| CN103768018A (zh) | 2012-10-17 | 2014-05-07 | 南京绿叶思科药业有限公司 | 一种卡巴他赛脂质体注射剂及其制备方法 |
| WO2014160337A1 (en) | 2013-03-13 | 2014-10-02 | Mallinckrodt Llc | Liposomal cisplatin compositions for cancer therapy |
| BR112015022819A8 (pt) * | 2013-03-13 | 2019-11-26 | Mallinckrodt Llc | método para a preparação de um taxano lipossomal, composição compreendendo um lipossoma e taxano lipossomal |
| NZ753214A (en) | 2016-11-11 | 2022-02-25 | Univ Western Health Sciences | Methods of treating upper tract urothelial carcinomas |
-
2017
- 2017-01-09 CN CN202110437727.6A patent/CN113181118A/zh active Pending
- 2017-01-09 BR BR112018013896A patent/BR112018013896A2/pt not_active IP Right Cessation
- 2017-01-09 DK DK17736515.2T patent/DK3400072T3/da active
- 2017-01-09 KR KR1020187000357A patent/KR20180103039A/ko unknown
- 2017-01-09 PE PE2018001211A patent/PE20181445A1/es unknown
- 2017-01-09 EA EA201891575A patent/EA038653B1/ru unknown
- 2017-01-09 JP JP2018500936A patent/JP6697541B2/ja not_active Expired - Fee Related
- 2017-01-09 MX MX2018008267A patent/MX2018008267A/es unknown
- 2017-01-09 US US16/066,836 patent/US11229602B2/en active Active
- 2017-01-09 ES ES17736515T patent/ES2863659T3/es active Active
- 2017-01-09 CA CA3009809A patent/CA3009809A1/en active Pending
- 2017-01-09 CR CR20180388A patent/CR20180388A/es unknown
- 2017-01-09 AU AU2017205337A patent/AU2017205337B2/en active Active
- 2017-01-09 CN CN201780002340.XA patent/CN108136217B/zh active Active
- 2017-01-09 EP EP17736515.2A patent/EP3400072B1/en active Active
- 2017-01-09 MY MYPI2018001179A patent/MY198105A/en unknown
- 2017-01-09 WO PCT/US2017/012720 patent/WO2017120586A1/en active Application Filing
- 2017-01-09 SG SG11201805594PA patent/SG11201805594PA/en unknown
-
2018
- 2018-06-28 IL IL260346A patent/IL260346B2/en unknown
- 2018-07-03 MX MX2020013858A patent/MX2020013858A/es unknown
- 2018-07-04 CL CL2018001838A patent/CL2018001838A1/es unknown
- 2018-07-06 PH PH12018501451A patent/PH12018501451A1/en unknown
- 2018-07-24 ZA ZA2018/04968A patent/ZA201804968B/en unknown
- 2018-07-25 CO CONC2018/0007674A patent/CO2018007674A2/es unknown
- 2018-11-09 HK HK18114340.8A patent/HK1255212A1/zh unknown
-
2019
- 2019-10-15 JP JP2019188572A patent/JP2020002181A/ja not_active Withdrawn
-
2021
- 2021-05-19 US US17/324,584 patent/US20210267896A1/en not_active Abandoned
-
2022
- 2022-09-12 JP JP2022144431A patent/JP2022168210A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805594PA (en) | Formulations for treating bladder cancer | |
| SG11201900344YA (en) | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201806515RA (en) | Eribulin-based antibody-drug conjugates and methods of use | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201810951RA (en) | Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201807965YA (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201810146SA (en) | Adenosine derivatives for use in the treatment of cancer | |
| SG11201903615WA (en) | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201803915UA (en) | Echinomycin formulation, method of making and method of use thereof | |
| SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
| SG11201901389XA (en) | Combination therapy with glutaminase inhibitors | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
| SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
| SG11201804268RA (en) | Conjugates of quaternized tubulysin compounds | |
| SG11201805385QA (en) | Bromodomain and extra-terminal protein inhibitor combination therapy |